Press Release No. 039/KFCP-DIR/PR/X/18
Jakarta, 28 October 2018 - PT Kalbe Farma Tbk. (Kalbe) along with the Indonesian Childhood Cancer Foundation (YOAI) inaugurated the Kalbe and YOAI Kids Polyclinic at Dharmais Cancer Hospital, Jakarta. The opening ceremony was conducted by Prof. Dr. dr. Nila Djuwita F. Moeloek SpM (K), Minister of Health of RI; accompanied Irawati Setiady, President Commissioner of PT Kalbe Farma Tbk' and witnessed by Prof. Dr. dr. H. Abdul Kadir, Ph.d, SpTHT-KL (K), MARS, Director Of Dharmais Cancer Hospital; and Rahmi Adi Putra Tahir, Chairperson of the Indonesian Childhood Cancer Foundation.
“Kalbe will continue to realize its commitment to public health, especially children's health in Indonesia,” said Irawati Setiady, President Commissioner of PT Kalbe Farma Tbk. “The presence of Kalbe and YOAI's Children's Polyclinic, we hope that we will provide sense of comfort for all of the child cancer patients here. We filled the Children's Polyclinic facility with a plethora of toys and reading materials so that children with cancer can still play and learn even without being in school,” Irawati continued.
“We are very glad of Kalbe’s willingness to renovate the Children Polyclinic area at the Dharmais Cancer Hospital, because this is in line with one of the Gold Ribbon YOAI program where we aim to collaborate with the donors to build an integrated means and infrastructure of childhood cancer countermeasures in Indonesia,” said Rahmi Adi Putra Tahir, Chairperson of the Indonesian Childhood Cancer Foundation. “We hope that with the Kalbe and YOAI's Children's Polyclinic, child cancer patients will no longer feel afraid or depressed to go to Dharmais Cancer Hospital, but would feel happy instead where they can play and forget about their illness,” continued Rahmi.
This Kids room was built through the donations drive done by the Kalbe Group's 3,200 employees and their families during the Kalbe Run event on 22 April 2018. Something different happened with the Kalbe Run event this year, which held the theme of ‘Run to Share.’ The Kalbe Run raised donations from its participants, Kalbe Group's employees, as well as from the registration fee; to be used to renovate the Children's Polyclinic at Dharmais Cancer Hospital in collaboration with the Indonesian Childhood Cancer Foundation (YOAI). The funds collected from this fundraising reached Rp 100 million.
“By setting aside a part of the registration fee, we collected a donation of Rp 100 million. Hopefully the ‘Run to Share’ movement by the employees of Kalbe Group can provide a little cheerfulness for children with cancer in facing their days at the Children's Polyclinic of Dharmais Cancer Hospital,” said Yoppy Hadi Soeyanto, Chairman of the 2018 Kalbe Run.
According to data from the WHO, every year the number of cancer patients in the world increased by about 6.25 million people; and in recent years the incidence of cancer in children is increasing. The number reached 110 to 130 cases per one million children each year. Currently in Indonesia there are approximately 11,000 cases of childhood cancer per year, of which 650 child cancer cases per year being in Jakarta. Most of children with cancer came from economically challenged families. The type of childhood cancers that are most prevalent in Indonesia are leukemia and Retinoblastoma. (source: http://www.yoaifoundation.org)
Indonesian Childhood Cancer Foundation (YOAI) at a glance
The Indonesian Childhood Cancer Foundation (YOAI) was established on 24 May 1993, by a number of parents, as a form of gratefulness for their child(ren)'s health who had cancer and gotten cured, through the assistance of sympathizers, volunteers, psychologists, and physicians. With the vision: Assisting the government's effort in the development of the fields of children's health, specifically the countermeasures of childhood cancer in Indonesia and increase public awareness of childhood cancer.
Kalbe at a glance
PT Kalbe Farma Tbk (“Kalbe”) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Brainact, Broadced, etc.); over-the-counter medication division (Woods, Promag, Mixagrip, Komix, Fatigon, etc.); health drinks (Hydro Coco, Extra Joss, Nitros); nutrition division (ChilKid, Prenagen, Diabetasol, etc.); and distribution division. Kalbe currently has more than 35 subsidiaries, 14 production facilities with international standard, and employs more than 17,000 employees dispersed across more than 72 branches throughout Indonesia. From 1991, Kalbe is listed at Indonesia Stock Exchange (IDX: KLBF).